Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06854224

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

Orexin Antagonism to Target Mechanisms of Suicide Risk: A Proof-of-Concept Clinical Trial

Sponsor: James J. Peters Veterans Affairs Medical Center

Conditions Major Depressive Disorder (MDD) Suicide Risk

Interventions Suvorexant (dual orexin receptor antagonist)

Updated 3 times since 2025 Last updated: Sep 22, 2025 Started: Sep 1, 2025 Primary completion: Jul 1, 2027 Completion: Jul 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Major Depressive Disorder (MDD) and Suicide Risk, this trial is actively recruiting participants. The trial is conducted by James J. Peters Veterans Affairs Medical Center and has accumulated 3 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE2
Apr 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

James J. Peters Veterans Affairs Medical Center
Marianne Goodman

Data source: Bronx Veterans Medical Research Foundation, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• The Bronx, United States